This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
27 Apr 2016

Eppendorf Centrifuge 5920 R: the new benchmark in capacity and performance

Also offers a powerful state-of-the-art refrigeration system with advanced temperature management.

Eppendorf’s new refrigerated Centrifuge 5920 R combines extraordinary high capacity with enhanced temperature management in a very compact and ergonomic product design.

Centrifuge 5920 R can accommodate up to 4 x standard 1 Liter Nalgene bottles, as well as up to 108 x 15 mL conical tubes, and 52 x 50 mL conical tubes, enabling researchers to spin large volumes at any one time, in applications such as bioprocessing or cell culture. Additionally, the universal rotor bucket design means researchers can spin both plates and tubes in the same bucket without the need to purchase separate plate buckets.

Eppendorf’s Centrifuge 5920 R also offers a powerful state-of-the-art refrigeration system with advanced temperature management, meaning users can be confident that their temperature-sensitive samples are safe. Dynamic compressor control technology and a FastTemp pro function also allows precise and automated pre-cooling based on a pre-programmable time and date.

Easy to use, the Centrifuge 5920 R features a multi-lingual menu with backlit display with 5 program keys enabling rapid access to routine programs, as well as an adjustable ECO shut-off function to save energy and increase compressor life. “With laboratories under increasing pressure to increase efficiencies and throughput we understand the challenges that researchers face in their work,” said Peter Schreiner, Global Product Manager Centrifugation at Eppendorf. “The very large capacity and precise temperature management offered by the Centrifuge 5920 R means researchers can be assured that not only are their samples safe, but that they are saving time, money and energy with this system.”

Related News

  • News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel

    A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to...
  • News Protecting life-saving therapies: CPHI Online Podcast Series

    The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.

  • News 2026 Outsourcing Outlook Update - pharma at a crossroads

    The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ...
  • News Roche maintains German investment commitment whilst rivals scale back

    Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.

  • News Women in Pharma: The History of CPHI Women in Japan

    Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive.
  • News EU drafts deal to end essential medicines shortage

    European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.

  • News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg

    The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th...
  • News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026

    CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.